Advanced search×

Once daily monotherapy with prolonged-release valproate minitablets given in the evening--a chronopharmacological study.

Int J Clin Pharmacol Ther 47(7):439-43 (2009) PMID 19640350

Chronopharmacological investigations concerning efficacy, side effects and circadian serum concentration are lacking for many antiepileptic drugs.

Version: za2963e q8za9 q8zb0 q8zc4 q8zd4 q8ze0 q8zf8 q8zg4

Similar articles you may find interesting…

  1. Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?

    Antimicrob Agents Chemother (2013) PMID 23650165

    We evaluated linezolid, dosed at 800 mg once daily for 1-4 months as guided by sputum culture status and tolerance, and then 1200 mg thrice weekly until ≥ 1 year after culture conversion, on top of individually optimized regimens among 10 consecutive patients with extensively drug-resistant tuberc...
  2. Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for r...

    J Med Econ (2013) PMID 23647445

    Results of the EPOC study are anticipated in early 2013 and will inform treatment selection by providing patient-centered data on therapy switch to fingolimod or standard-of-care DMTs. Trial Registration: ClinicalTrials.gov NCT01216072....
  3. Real-life effectiveness and tolerability of rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: The EMBRAC...

    Curr Med Res Opin (2013) PMID 23647369

    Rivastigmine transdermal patch is effective in maintaining cognitive function over 18 months of treatment in patients with mild-to-moderate AD. The safety profile was comparable to the data in the Canadian product monograph. Lack of a comparator group is a potential limitation of the study....